Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: From standard therapy to novel approaches

Monika Engelhardt, Martina Kleber, Josefina Udi, Ralph Wsch, Andrew Spencer, Francesca Patriarca, Stefan Knop, Benedetto Bruno, Martin Gramatzki, Fortunato Morabito, Martin Kropff, Antonino Neri, Orhan Sezer, Rom Hajek, Donald Bunjes, Mario Boccadoro, Christian Straka, Michele Cavo, Aaron Polliack, Hermann EinseleAntonio Palumbo

Research output: Contribution to journalArticlepeer-review


Treatment for multiple myeloma (MM) has changed beyond recognition over the past two decades. During the early 1980s, MM inevitably resulted in a slow progressive decline in quality of life until death after about 2 years, while today patients can expect a 50 chance of achieving a complete remission, median survival of 5 years, and a 20 chance of surviving longer than 10 years. An international expert opinion meeting (including members of the GIMEMA and DSMM study groups) was held in 2009. One of the outcomes of the meeting was the development of a consensus statement outlining contemporary optimal clinical practice for the treatment of MM. The international panel recommended that the state of the art therapy for MM should comprise: (a) evidence-based supportive care, (b) effective and well-tolerated chemotherapeutic regimens, (c) autologous hematopoietic stem cell transplant (ASCT) for patients suitable for intensive conditioning therapy, and (d) evidence-based incorporation of novel anti-MM agents. Maintenance strategies have also become increasingly important for the prolongation of remission after front-line therapies. In addition, improved understanding of the biology of MM has led to the development of novel biological therapeutic agents such as thalidomide, lenalidomide, bortezomib, and others. These agents specifically target intracellular mechanisms and interactions, such as those within the bone marrow microenvironment, and have been integrated into MM treatment. This report reviews recent clinical advances in the treatment strategies available for MM and provides an overview of the state of the art management of patients with MM.

Original languageEnglish
Pages (from-to)1424-1443
Number of pages20
JournalLeukemia and Lymphoma
Issue number8
Publication statusPublished - Aug 2010


  • chemotherapy
  • molecular targets
  • Multiple myeloma (MM)
  • novel agents
  • transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: From standard therapy to novel approaches'. Together they form a unique fingerprint.

Cite this